



Supplemental Figure 1. The absolute numbers of CD8<sup>+</sup> and CD8<sup>+</sup>CD103<sup>-</sup> T cells in the non-tumor and tumor tissues of the 50 GC patients. Non-tumor and tumor tissue-derived cell suspensions were stained with Fixable Viability Stain 700 (FVS700), anti-CD45, CD3, CD8 and CD103 antibodies, then FVS700<sup>-</sup>CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> cells (CD8<sup>+</sup> T cells) and FVS700<sup>-</sup>CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>CD103<sup>-</sup> cells (CD8<sup>+</sup>CD103<sup>-</sup> T cells) per million cells were analyzed.  $P < 0.05$  was considered as statistically significant.

Supplemental Table 1. Clinical Characteristics of 155 GC Patients

Variables	No. of patients (group 1)	No. of patients (group 2)
Sex (male/female)	31/19	83/22
Age (y), median (range)	61, 30-86	62, 27-79
Tumor size (cm; <5/≥5)	36/14	84/21
Neural invasion (absent/present)	35/15	91/14
Vascular invasion (absent/present)	39/11	89/16
Tumor (T) invasion (T1+T2/T3+T4)	23/27	25/80
Lymphoid nodal (N) status (N0 / N1+N2+N3)	28/22	41/64
Distant metastasis (M) status (M0/M1)	49/1	100/5
TNM stage ( I + II /III+IV)	32/18	45/60

Supplemental Table 2. Fluorochrome-conjugated antibodies used in flow cytometry.

Antibodies	Source
Fixable Viability Stain 700	BD Pharmingen
APC-H7 conjugated anti-human CD3	BD Pharmingen
APC conjugated anti-human CD103	Biolegend
Alexa Fluor 488-conjugated anti-human GITR	Biolegend
Alexa Fluor 488-conjugated anti-human LAG-3	Biolegend
Alexa Fluor 488-conjugated anti-human Ki-67	Biolegend
Brilliant Violet 605 anti-human CD69	Biolegend
FITC-conjugated anti-human CD45RA	Biolegend
FITC-conjugated anti-human CD28	Biolegend
FITC-conjugated anti-human CD127	Biolegend
FITC-conjugated anti-human CD39	Biolegend
FITC-conjugated anti-human Tim-3	Biolegend
FITC-conjugated anti-human 2B4	Biolegend
FITC-conjugated anti-human BTLA	Biolegend
FITC-conjugated anti-human TNF- $\alpha$	Biolegend
FITC-conjugated anti-human granzyme A	Biolegend
FITC-conjugated anti-human granzyme B	Biolegend
PE-conjugated anti-human CCR7	Biolegend
PE-conjugated anti-human CD27	Biolegend
PE-conjugated anti-human KLRG1	Biolegend
PE-conjugated anti-human 4-1BB	Biolegend
PE-conjugated anti-human OX40	Biolegend
PE-conjugated anti-human CD73	Biolegend
PE-conjugated anti-human PD-1	Biolegend
PE-conjugated anti-human TIGIT	Biolegend
PE-conjugated anti-human IFN- $\gamma$	Biolegend
PE-conjugated anti-human granzyme K	Biolegend
PE-conjugated anti-human granzysin	Biolegend
PE-conjugated anti-human perforin	Biolegend
PE-Cy7-conjugated anti-human CD45	Biolegend
PerCP-Cy5.5-conjugated anti-human CD8	Biolegend

Supplemental Table 3. Univariate and Multivariate Analyses of Factors Associated With Survival and Recurrence

Variables	Overall Survival				Disease-free Survival			
	Univariate	Multivariate			Univariate	Multivariate		
	<i>P</i>	HR	95.0% CI	<i>P</i>	<i>P</i>	HR	95.0% CI	<i>P</i>
Sex (male vs. female)	0.130			NA	0.131			NA
Age, years ( $\geq 62$ vs. $< 62$ )	0.279			NA	0.315			NA
Tumor size, cm ( $\geq 5$ vs. $< 5$ )	0.001	0.454	0.219-0.943	0.034	0.002	0.495	0.238-1.031	0.060
Histologic type (diff vs. undiff)	0.102			NA	0.116			NA
Neural invasion (present vs. absent)	0.002	1.894	0.795-4.511	0.149	0.001	2.025	0.839-4.883	0.116
Vascular invasion (present vs. absent)	0.009	1.663	0.702-3.940	0.247	0.007	1.884	0.786-4.514	0.156
Tumor (T) invasion (T1+T2 vs. T3+T4)	0.012	1.433	0.234-8.766	0.697	0.012	1.455	0.238-8.889	0.685
Lymphoid nodal (N) status (N0 vs. N1+N2+N3)	0.014	0.529	0.179-1.570	0.251	0.013	0.602	0.206-1.756	0.353
Distant metastasis (M) status (M0 vs. M1)	0.017	3.393	0.978-11.779	0.054	0.007	4.650	1.307-16.541	0.018
TNM stage (I+II vs. III+IV)	<0.001	3.506	0.771-15.932	0.104	<0.001	3.011	0.665-13.632	0.152
CD8 <sup>+</sup> CD103 <sup>+</sup> cell number (high vs. low)	0.005	2.205	1.005-4.841	0.049	0.003	2.302	1.044-5.076	0.039

NOTE: Cox proportional hazards regression model. Variables used in multivariate analysis were adopted by univariate analysis. TNM, tumor node metastasis; diff, differentiation; undiff, undifferentiation; CI, confidence interval; HR, hazard ratio; NA, not adopted.